ArticleEuropean journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery2025
Oncological and Surgical Outcomes of Left Trisegmentectomy or Lingulectomy Versus Upper Lobectomy for Early-Stage Non-Small Cell Lung Cancer: A Multicentre Study.
Article in European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Transformer-Based PET/CT Fusion Enables Preoperative Prediction and Prognostic Stratification of Spread Through Air Spaces in Lung Adenocarcinoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesLeft upper lobe and right upper and middle lobes have a similar anatomical structure; therefore, multi-segmentectomy (S), as upper trisegmentectomy and lingulectomy, should guarantee the same oncological radicality as left upper lobectomy (LUL). The aim of the study was to compare the oncological and surgical outcomes of left upper S (trisegmentectomy or lingulectomy) and LUL for early-stage (cT1-T2bN0M0) non-small cell lung cancer (NSCLC).
methodsClinical data of patients who underwent S or LUL, without any previous neoadjuvant treatment, from June 2016 to March 2024 at 9 high-volume centres, were retrospectively reviewed. To reduce any selection bias, a 1:1 propensity score matching (PSM) was performed.
resultsAfter PSM, 105 patients, with comparable clinical-pathological characteristics, were included in each group. A significant difference between LUL and S was recorded in terms of postoperative complications (P = .014), mainly air-leak (P = .055), without differences in hospitalization (P = .333). The median follow-up (FUP) time was 23 months (interquartile range [IQR]: 13-42). The 5-year overall survival (OS) and disease-free survival (DFS) were 95% vs 80% (P = .072) and 97%vs 83%(P = .090) for LUL and S, respectively. When analysing only cases with tumour-to-margin distance of <1 cm, the 5-year OS and DFS were LUL: 98% vs S: 64%(P = .049) and LUL: 96% vs S: 87%(P = .056), respectively. If the distance was > 1 cm, the 5-year OS (P = .193) and DFS (P = .351) were comparable in both groups, as for tumour-diameter > 2 cm (5-year OS (P = .429) and DFS (P = .602)). In the S cohort, no difference was found between lingulectomy and trisegmentectomy in terms of 5-year OS (P = .240) and DFS (P = .304). At multivariable analysis, positive spread-through air spaces (STAS) was the only significant predictor for DFS in S group (P = .027).
conclusionsOncological outcomes of left upper trisegmentectomy or lingulectomy for early-stage NSCLC are comparable with those of LUL, if the tumour is located more than 1 cm from the surgical margin. Positive STAS is the only predictor for shorter DFS in S group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.